A phase 2 multiple ascending dose study of the inhaled pan-JAK inhibitor nezulcitinib (TD-0903) in severe COVID-19.

Dave Singh,Maxim Boguş,Valentyn Moskalenko,RW Lord,Edmund J. Moran,Glenn Crater,David L. Bourdet,Nathan D. Pfeifer,Jacky Woo,Elad Kaufman,David A. Lombardi,Emily Y Weng,Tuan Nguyen,Ashley Woodcock,Brett Haumann,Rajeev Saggar

A phase 2 multiple ascending dose study of the inhaled pan-JAK inhibitor nezulcitinib (TD-0903) in severe COVID-19.

2021

Dave Singh
Maxim Boguş
Valentyn Moskalenko
RW Lord
Edmund J. Moran
Glenn Crater
David L. Bourdet
Nathan D. Pfeifer
Jacky Woo
Elad Kaufman
David A. Lombardi
Emily Y Weng
Tuan Nguyen
Ashley Woodcock
Brett Haumann
Rajeev Saggar

The inhaled lung-selective pan-JAK inhibitor nezulcitinib appears generally well tolerated in hospitalised patients with severe #COVID-19, with trends for improved oxygenation and clinical status, shortened hospitalisation, and fewer deaths vs placebo.

Keywords:

severe acute respiratory syndrome coronavirus 2
Medicine
Gastroenterology
Internal medicine
Oxygenation
Coronavirus disease 2019
Placebo
2019 20 coronavirus outbreak

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations